Last reviewed · How we verify
Acular, Xibrom
At a glance
| Generic name | Acular, Xibrom |
|---|---|
| Sponsor | Innovative Medical |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effectiveness of Periocular Drug Injection in CATaract Surgery (PHASE3)
- Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
- Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
- Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas (2)
- A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification (PHASE4)
- A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification (PHASE4)
- A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID) (PHASE4)
- Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5% (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acular, Xibrom CI brief — competitive landscape report
- Acular, Xibrom updates RSS · CI watch RSS
- Innovative Medical portfolio CI